Navigation Links
Shire Announces Positive Results of Studies With Guanfacine,Extended Release, An Investigational Nonstimulant Medication Filed,for the Treatment of ADHD in Children and Adolescents

SAN DIEGO, May 23, 2007 /PRNewswire-FirstCall/ -- Shire plc announced today the positive results of studies of the investigational medication guanfacine extended release (GXR, previously referred to as SPD503), a selective alpha-2A-adrenoceptor agonist. These data from two short-term phase III placebo-controlled studies and two long-term phase III open-label studies, presented at the 2007 American Psychiatric Association (APA) annual meeting, demonstrated that GXR significantly improved all core symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in children aged 6 to 17 years.

"Guanfacine extended release, the first selective alpha-2A-adrenoceptor agonist to be tested in well-controlled studies as a treatment for ADHD, holds potential based on the significant improvements in ADHD symptoms documented in four studies of this investigational drug," stated co-author Joseph Biederman, M.D., lead investigator, chief of clinical and research program in pediatric psychopharmacology at Massachusetts General Hospital and professor of psychiatry at Harvard Medical School. "Moreover, these data presented at this medical conference add evidence that GXR when dosed once daily may continue to control children's ADHD symptoms for up to 24 months."

GXR, a nonstimulant, is not a controlled substance and does not appear to have a mechanism for potential abuse or dependence. Shire submitted a New Drug Application (NDA) for GXR on August 24, 2006, which is currently under FDA review. The NDA provided data on GXR 1 mg to 4 mg taken once daily for the treatment of children and adolescents with ADHD.

GXR Yielded Significant Reductions in ADHD-RS-IV Scores in Two Short-Term Trials

Results from two short-term, double-blind, randomized phase III clinical trials presented at this medical conference, demonstrated that GXR significantly controlled all core symptoms of ADHD, including inattention, hyperac
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Shire to Present New Scientific Data on ADHD Treatment Portfolio at APA Annual Meeting
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:7/28/2014)... -- Syneron Medical Ltd. (NASDAQ: ELOS ), a ... new PicoWay® device has received CE Mark indication to ... lesions on any skin type. PicoWay is a new ... wavelengths, which utilizes Syneron,s proprietary PicoWay technology to deliver ... of a second, known as picosecond pulses. Syneron will ...
(Date:7/28/2014)... July 28, 2014  ALPHAEON Corporation ... healthcare and subsidiary of Strathspey Crown ... Recommended Nutriceuticals (PRN) ® , a leading ... products for dry eye and macular ... transaction worth up to $55M. ...
(Date:7/28/2014)... , July 28, 2014 Concord Medical ... CCM ), a leading specialty hospital management ... radiotherapy and diagnostic imaging centers in China ... its Board of Directors declared a special cash dividend ... Depositary Share ("ADS")) on the Company,s outstanding ordinary shares. ...
Breaking Medicine Technology:Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 2Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 3Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 4ALPHAEON Acquires PRN, A Leading Specialty Nutriceutical Company 2ALPHAEON Acquires PRN, A Leading Specialty Nutriceutical Company 3Concord Medical Declares Special Dividend 2
... , WASHINGTON, Dec. 11 Nabe News ... medicines are in development to fight diabetes. The report details a ... clinical trials and awaiting approval by the U.S. Food and Drug Administration. ... ( PhRMA ). , Diabetics do not produce or properly use ...
... R.I., Dec. 11 CVS Caremark (NYSE: CVS ... Vice President and Chief Human Resources Officer, effective January 1, ... his retirement. , (Logo: http://www.newscom.com/cgi-bin/prnh/20090226/NE75914LOGO ) , ... has more than 30 years of human resources experience. ...
Cached Medicine Technology:183 New Medicines in Development for Diabetes 2CVS Caremark Names New Chief Human Resources Officer 2
(Date:7/28/2014)... 28, 2014 A lush green lawn offers ... the summer. However, the summer heat, lack of rain, foot ... brown, weak and unhealthy. The Grounds Guys recommends these suggestions ... a lawn once a week and set the height on ... protects the grass roots from heat and allows roots to ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 A January ... reduction of gluten intake in those who were self-diagnosed ... Mittry, director of nutrition for San Diego health and ... various gluten considerations for those who are unclear about ... explains that gluten is a protein, found in wheat, ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Quincy Bioscience, ... , is pleased to announce the release of the ... company president and co-founder Mark Underwood. , The Brain ... information, offering useful techniques for readers to improve memory ... an unavoidable conclusion, The Brain Health Guide provides ways ...
(Date:7/28/2014)... Dawn Echols’ professional background spans success in ... experience has honed her people skills and led ... counseling ( http://dawningphoenix.com ) work includes private practice, ... domestic violence. , As owner and executive ... individuals and groups for a variety of disorders. ...
(Date:7/28/2014)... -- Elementary school students seem to be satisfied with the ... new study of school officials. , , New meal standards ... into effect in the fall of 2012. At the time, ... throw away most of their food. But the new study ... case. , , "The updated meals standards are resulting in ...
Breaking Medicine News(10 mins):Health News:Nurturing Lawns in the Summer Heat: The Grounds Guys® Offers Tips on Caring for Lawns This Summer 2Health News:VeraVia Explains the Basics of Gluten-Intolerance Following Industry Study 2Health News:VeraVia Explains the Basics of Gluten-Intolerance Following Industry Study 3Health News:Quincy Bioscience Launches the Fourth Edition of The Brain Health Guide 2Health News:Dawn M. Echols, M.S., LPC of Dawning Phoenix Speaks at Newly Formed Task Force 2Health News:Healthy School Lunches Get Thumbs Up From Students 2
... Infuser, a,medical device used extensively in Combat Support Hospitals to treat ... to,save the life of an Omaha, NE Police Officer. , ... during a traffic stop. One of the bullets,hit him in the ... "Injury to this area is ...
... don,t respond at first not helped by maintenance treatment, ... Maintenance therapy using low-dose peginterferon doesn,t help patients with ... initial round of treatment, new research suggests. , The ... with liver disease over the course of four years. ...
... can outperform animal and human derived serum in CHO cell culture. ... ... -- Cellastim has proven to be a robust replacement for serum ... kinetics and productivity of CHO cell lines across a variety of ...
... statement by Betsy Ryan, President and CEO, New Jersey Hospital ... today announced that six New Jersey hospitals will share funding ... news for those facilities, but the more sobering headline is ... away. While a worthy effort, clearly the needs of New ...
... Calif., Dec. 3 ThermoGenesis,Corp. (Nasdaq: KOOL ... process and store adult stem cells, said today that ... Board of Directors to resign as,the Chief Executive Officer ... board has named Matthew T. Plavan, the Company,s Executive,Vice ...
... Dec. 3 The makers of TYLENOL(r) Warming,Liquids have embarked ... so they can warm up. Already a success in New ... complimentary,transportation within the city limits. , ... the city limits of the,District of Columbia, with a maximum ...
Cached Medicine News:Health News:Belmont(R) Rapid Infuser Helps Save Officer's Life 2Health News:Hepatitis C Therapy Useless for Some 2Health News:InVitria's Cellastim Delivers Superior Results in CHO Cell Culture 2Health News:ThermoGenesis Announces Management Transition; Provides Update on Operational Milestones 2Health News:ThermoGenesis Announces Management Transition; Provides Update on Operational Milestones 3Health News:ThermoGenesis Announces Management Transition; Provides Update on Operational Milestones 4Health News:ThermoGenesis Announces Management Transition; Provides Update on Operational Milestones 5Health News:The Makers of TYLENOL(R) Warming Liquids Offer Free 'Warming' Taxi Rides in Washington, D.C. 2
Stryker Instruments, the leader in surgical helmets, offers its 4th generation of personal protection systems for todays surgical environment the Sterishield T4 System....
... The PROVISION Surgical Helmet System from ... and protection. This system helps meet OSHA ... body fluids, while creating a new standard ... addition to the PROVISION Helmet System from ...
...
... ground has a large surface ... For use with minicrocodile clip ... (1.75 in) long, 3.1 cm ... package contains 50 individually sealed ...
Medicine Products: